Insilico Medicine is moving its AI-discovered drug, rentosertib, into Phase III clinical trials for idiopathic pulmonary fibrosis (IPF). The drug, which targets the TNIK protein, showed promising results in Phase II trials with a significant improvement in lung function for patients receiving a 60 mg daily dose. This advancement highlights the potential of AI in accelerating drug discovery and development, reducing the time from project initiation to preclinical candidate nomination to 18 months. AI
IMPACT Accelerates the validation of AI-discovered therapeutics, potentially reducing drug development timelines and costs.
RANK_REASON The cluster reports on a drug identified and designed by AI that has reached Phase III clinical trials, a significant milestone in AI-driven drug discovery.
Read on Artificial Intelligence News →
- Chemistry42
- idiopathic pulmonary fibrosis
- Insilico Medicine
- PandaOmics
- Phase III human trials
- rentosertib
- TNIK protein
- FDA
AI-generated summary · Google Gemini · from 2 sources. How we write summaries →
